Eli Lilly raises revenue outlook on weight-loss drug demand

Summary

Eli Lilly has raised its revenue outlook on sales of its weight-loss drugs, the second upgrade in three months. The Financial Times reports that the US drugmaker's profits surged on demand for the drugs and that its shares hit a new record. Investing.com reports that the company also trimmed its profit view because of deal charges.

Timeline

1. Investing.com

   29 Oct 2026, 10:48 UTCSource ↗

   Investing.com reports that Eli Lilly lifted its revenue outlook on weight-loss drug sales while trimming its profit view because of deal charges.

2. Financial Times

   29 Oct 2026, 17:26 UTCSource ↗

   The Financial Times reports that Eli Lilly's profits surged on demand for weight-loss drugs, with shares hitting a new record as the US drugmaker raised its revenue outlook for the second time in three months.